Prenetics Global (NASDAQ:PRE) Shares Up 3.2% - Here's What Happened

Prenetics Global Limited (NASDAQ:PRE - Get Free Report) shares were up 3.2% during trading on Thursday . The stock traded as high as $16.97 and last traded at $16.49. Approximately 170,202 shares traded hands during trading, an increase of 25% from the average daily volume of 136,406 shares. The stock had previously closed at $15.98.Get Prenetics Global alerts:Analysts Set New Price TargetsSeveral equities research analysts have issued reports on PRE shares. Wall Street Zen upgraded shares of Prenetics Global from a "hold" rating to a "buy" rating in a research note on Saturday, November 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Prenetics Global in a report on Wednesday, October 8th. Finally, Cantor Fitzgerald upped their target price on Prenetics Global from $26.00 to $32.00 and gave the stock an "overweight" rating in a report on Wednesday, October 29th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Prenetics Global currently has an average rating of "Hold" and a consensus price target of $32.00.Read Our Latest Report on Prenetics GlobalPrenetics Global Stock Up 3.2%The firm has a 50 day simple moving average of $14.19 and a 200-day simple moving average of $10.84. The stock has a market cap of $277.53 million, a P/E ratio of -8.12 and a beta of 0.35. Prenetics Global (NASDAQ:PRE - Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.14. Prenetics Global had a negative return on equity of 30.12% and a negative net margin of 60.70%.The company had revenue of $23.56 million during the quarter, compared to the consensus estimate of $26.00 million. On average, equities analysts anticipate that Prenetics Global Limited will post -3.3 earnings per share for the current year. Hedge Funds Weigh In On Prenetics GlobalSeveral large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. bought a new stake in shares of Prenetics Global during the 3rd quarter worth about $65,000. Stevens Capital Partners acquired a new stake in Prenetics Global during the second quarter worth approximately $137,000. UBS Group AG boosted its holdings in shares of Prenetics Global by 581.9% during the third quarter. UBS Group AG now owns 46,561 shares of the company's stock worth $619,000 after acquiring an additional 39,733 shares during the period. Aberdeen Group plc acquired a new position in shares of Prenetics Global in the third quarter valued at approximately $979,000. Finally, Nomura Holdings Inc. increased its stake in shares of Prenetics Global by 3.3% during the first quarter. Nomura Holdings Inc. now owns 333,528 shares of the company's stock worth $1,307,000 after purchasing an additional 10,576 shares during the period. 25.01% of the stock is owned by institutional investors. Prenetics Global Company Profile (Get Free Report)Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.Recommended StoriesFive stocks we like better than Prenetics GlobalESG Stocks, What Investors Should KnowBroadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $5003 Stocks to Protect Your Portfolio from the Coronavirus Contagion Forget the Chips: 4 Industrial Plays for the AI Rebound3 Tickers Leading a Meme Stock RevivalMongoDB Could Hit Record Highs—But You’ll Need to Move FastThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Prenetics Global Right Now?Before you consider Prenetics Global, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.While Prenetics Global currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here